This Top 10% Earnings Machine Just Reported Skyrocketing Profits

Dexcom (DXCM) stock jumped late Thursday after the maker of devices for diabetes patients beat Wall Street’s fourth-quarter expectations and reiterated its sales outlook for 2023.

X

The company makes continuous glucose monitors, or CGMs, for patients with diabetes. These body-worn devices keep tabs on blood sugar in real time. During the December quarter, sales increased 17% to $815.2 million. On an organic basis, sales surged 20%. That beat expectations for $810 million in sales.

Now, Dexcom is focusing on a full U.S. launch of its newest CGM, dubbed G7. The Food and Drug Administration cleared G7 for people age 2 and older last year, following the European clearance.

“As we move into 2023, we are very excited to officially bring G7 to the U.S. market and further advance our strategic initiatives to reach millions of additional people that could benefit from Dexcom CGM,” Chief Executive Kevin Sayer said in written remarks.

In after-hours trading on the stock market today, Dexcom stock jumped 1.8% near 109.20. Shares are currently consolidating with a buy point at 125.65, according to MarketSmith.com.

Dexcom Stock: Earnings Skyrocket

Promisingly, Dexcom earned 34 cents per share, minus some items, in the fourth quarter. Dexcom stock analysts predicted 27 cents per share. Earnings reversed from a 1-cent loss in the year-ago period.

The strong earnings are reflected in Dexcom’s EPS Rating of 90. This puts Dexcom stock in the leading 10% of all stocks when it comes to recent profitability, according to IBD Digital.

Dexcom reiterated its 2023 outlook for $3.35 billion to $3.49 billion in sales. At the midpoint of $3.42 billion, revenue would climb roughly 17.5%. The midpoint missed more bullish expectations for $3.47 billion. Dexcom stock analysts also forecast earnings of $1.06 per share.

Dexcom stock analysts had projected earnings of $1.06 per share and $3.47 billion in sales.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

AbbVie Rises As Lagging Profit Outlook Better Than Feared In Humira Battle Year

AstraZeneca Hits Its Stride On Upbeat Guidance With ‘Desirable’ Growth

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Join IBD Live For Stock Ideas Each Morning Before The Open

Options Trading: How To Start Using Options, How To Manage Risk